Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

This study has been completed.
Information provided by:
Cylene Pharmaceuticals Identifier:
First received: October 27, 2008
Last updated: June 13, 2011
Last verified: June 2011
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2010
  Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)